活动性肢端肥大症患者血清硬骨素水平升高
本研究为横断面研究,比较30例活动性肢端肥大症患者与30名健康志愿者的血清硬骨素水平。患者组硬骨素中位数29.95 ng/mL,对照组22.44 ng/mL(P < 0.05)。硬骨素与IGF-1(rho = 0.54;P < 0.01)及GH(rho = 0.41;P < 0.05)呈中度正相关。作者认为高硬骨素水平可能参与肢端肥大症患者骨折风险增加。
要点
- 活动性肢端肥大症患者血清硬骨素中位数29.95 ng/mL,健康对照22.44 ng/mL(P < 0.05)。
- 硬骨素与IGF-1呈中度正相关(rho = 0.54;P < 0.01)。
- 硬骨素与GH呈中度正相关(rho = 0.41;P < 0.05)。
核心结论
- 高硬骨素水平可能参与活动性肢端肥大症患者骨折风险增加。
研究设计与样本
- 横断面研究,比较30例活动性肢端肥大症患者(男/女:14/16,平均年龄47.26 ± 12.52岁,范围18-64岁)与健康志愿者(男/女:17/13,平均年龄44.56 ± 10.74岁,范围19-62岁)的血清硬骨素水平。
- 采用电化学发光法测定IGF-1和GH,采用ELISA测定血清硬骨素。
主要发现
- 患者组GH中位数2.49 ng/mL(范围0.22-70.00 ng/mL;IQR 1.3-4.52),IGF-1中位数338.5 ng/mL(范围147-911 ng/mL;IQR 250-426)。
- 对照组GH中位数0.95 ng/mL(范围0.3-2.3 ng/mL),IGF-1中位数144 ng/mL(范围98-198 ng/mL)。
- 患者组硬骨素中位数29.95 ng/mL(范围7.5-78.1 ng/mL;IQR 14.37-37.47),对照组22.44 ng/mL(范围8.45-36.44 ng/mL;IQR 13.71-27.52),P < 0.05。
- 硬骨素与IGF-1呈中度正相关(rho = 0.54;P < 0.01)。
- 硬骨素与GH呈中度正相关(rho = 0.41;P < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Bone mineral density is normal in acromegalic patients and the cause of increased fracture risk that characterizes active acromegaly is unknown. OBJECTIVE: This study compared serum sclerostin levels between patients with active acromegaly and healthy individuals. DESIGN, SETTING, AND PARTICIPANTS: The serum sclerostin levels of patients with active acromegaly were compared with those of healthy volunteers in a cross-sectional study. The mean age of the 30 acromegaly patients (male/female: 14/16) was 47.26 ± 12.52 years (range, 18-64 years) and that of the healthy volunteers (male/female: 17/13) was 44.56 ± 10.74 years (range, 19-62 years). IGF-1 and GH levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an ELISA. The Mann-Whitney U test was used to compare sclerostin levels between the 2 groups. The correlations of sclerostin level with IGF-1 and GH were determined using Spearman's test. RESULTS: The 2 groups did not differ in age or sex (P > 0.05). The median GH and IGF-1 levels in the patient group were 2.49 ng/mL (range, 0.22-70.00 ng/mL) (interquartile range [IQR], 1.3-4.52) and 338.5 ng/mL (range, 147-911 ng/mL) (IQR, 250-426), respectively. The median GH and IGF-1 levels in the control group were 0.95 ng/mL (range, 0.3-2.3) and 144 ng/mL (range, 98-198), respectively. The median sclerostin level was 29.95 ng/mL (range, 7.5-78.1 ng/mL) (IQR, 14.37-37.47) in the acromegaly group and 22.44 ng/mL (range, 8.45-36.44 ng/mL) (IQR, 13.71-27.52) in the control group (P < 0.05). There was a moderate positive correlation between the sclerostin and IGF-1 levels (rho = 0.54; P < 0.01), and between the sclerostin and GH levels (rho = 0.41; P < 0.05). CONCLUSIONS: High sclerostin levels may contribute to the increased fracture risk seen in patients with acromegaly.
引用
- Pekkolay Z, Kılınç F, Gozel N, et al. Increased Serum Sclerostin Levels in Patients With Active Acromegaly. J Clin Endocrinol Metab. 2020. PMID: 31821453. doi:10.1210/clinem/dgz254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。